single_b

Single B cell screening is evolving fast. Biointron highlights emergent technologies that boost efficiency, speed, and precision in antibody discovery.

Hybridoma technologies laid the foundation for antibody discovery. Biointron explains conventional methods and their lasting value in monoclonal development.

AbDrop™ accelerates antibody discovery timelines. Biointron demonstrates how the platform isolates diverse leads within days, delivering speed and efficiency.

Single-cell antibody sequencing reveals repertoire diversity. Biointron applies this method to uncover potent candidates for therapeutic antibody programs.

High-throughput single B cell screening is transforming discovery. Biointron demonstrates how advanced platforms accelerate identification of potent antibodies.

Microfluidic technology is transforming biotechnology. Biointron shows how microfluidics enhance antibody research with precision, speed, and innovative applications.

Single B cell screening accelerates discovery. Biointron demonstrates how this technology identifies potent antibodies faster, guiding therapeutic development.

Single B cell technology accelerates antibody discovery. Biointron demonstrates how this approach delivers potent candidates faster and with greater precision.

High-throughput antibody production changes the pace of biotech. Learn how automation and  Single B Cell Screening deliver thousands of antibodies with speed and quality.

Biointron established a single-B cell antibody discovery platform based on microfluidic technology. Combined with our proprietary fast antibody expression platform, it has been proven to be fast and efficient in many projects.